Imugene Limited (IUGNF)
OTCMKTS · Delayed Price · Currency is USD
0.2000
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Imugene Revenue
In the fiscal year ending June 30, 2025, Imugene had annual revenue of 4.40M AUD, down -11.53%. Imugene had revenue of 3.14M in the half year ending June 30, 2025, a decrease of -54.94%.
Revenue
4.40M AUD
Revenue Growth
-11.53%
P/S Ratio
20.57
Revenue / Employee
879.36K AUD
Employees
5
Market Cap
59.29M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.40M | -573.22K | -11.53% |
| Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
| Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
| Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
| Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Nuo Therapeutics | 2.61M |
| Harvard Apparatus Regenerative Technology | 743.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Imugene News
- 2 months ago - Imugene And JW Therapeutics Collaborate On Solid Tumor Therapy - Nasdaq
- 2 months ago - Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours - PRNewsWire
- 7 months ago - Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL - PRNewsWire
- 7 months ago - Imugene set to dazzle market with new clinical data, cash call - The Australian Financial Review
- 1 year ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 2 years ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 2 years ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 2 years ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire